CTS — CTS Corporation

CTS Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Sales: $139 million, an 11% increase year-over-year and a 1% sequential increase from Q4 2025.
• Diversified End Markets: Sales up 18% year-over-year; Transportation sales grew 3%.
• Gross Margin: 39.5%, up 250 basis points year-over-year, driven by operational improvements and favorable end market mix.
• Adjusted Diluted Earnings Per Share: $0.62, up from $0.44 in Q1 2025.
• Cash Flow: Generated $17 million in operating cash flow; cash balance at $91 million with $63 million in borrowings.
• Shareholder Returns: $10 million returned through dividends and share buybacks in Q1 2026.

2. Strategic Updates and Business Highlights:

• Continued execution of diversification strategy with strong bookings in industrial and medical markets.
• New customer acquisitions in defense and transportation sectors.
• Robust performance in the medical market, with sales up 28% year-over-year, driven by strong demand in therapeutic applications.
• Aerospace and Defense sales increased by 11% year-over-year, with expectations for improved government funding in the second half of 2026.
• Industrial market sales grew 14% year-over-year, supported by stable OEM demand and distribution recovery.

3. Forward Guidance and Outlook:

• 2026 Sales Guidance: Narrowed to $560 million to $580 million; adjusted diluted EPS expected in the range of $2.35 to $2.45.
• Anticipated solid demand in diversified end markets, particularly in medical and industrial.
• Cautious outlook for transportation markets, with expectations of a decline in global light vehicle volumes but growth in commercial vehicles.

4. Bad News, Challenges, or Points of Concern:

• Potential economic impacts from geopolitical conflicts and supply chain issues related to petroleum products and rare earth materials.
• Transportation market production volumes expected to decline due to geopolitical uncertainties, with IHS forecasting a softening in global light vehicle volumes.
• Cost pressures from inflation in precious metals and oil-derived products, which could impact gross margins moving forward.

5. Notable Q&A Insights:

• Management confirmed no revenue pull-forward occurred in Q1 2026.
• Gross margin differentials exist between diversified markets and transportation, with medical having the highest margins.
• The company is actively managing cost pressures and working with customers to mitigate impacts on margins.
• Expectations for defense bookings to pick up in the latter half of the year, with potential delays in government funding affecting near-term performance.
• Continued focus on organic growth and strategic acquisitions, with no immediate M&A announcements but an active pursuit of opportunities.

This summary encapsulates the key takeaways from CTS Corporation's Q1 2026 earnings call, highlighting both the positive performance metrics and the challenges ahead.